Download PQ62570 attache document

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript 
Drug:
Disease
Everolimus
Renal Cell
Breast Cancer
Carcinoma
2nd line treatment
of metastatic renal
Indication
cell carcinoma
where patient is
intolerant of NICE
approved axitinib
Status
In development
Publication date
12 month cost impact
2nd line treatment of hormone receptor positive,
HER2 negative advanced breast cancer, in
combination with exemestane, in post
menopausal women without symptomatic visceral
disease after recurrence or progression following
a non steroidal aromatase inhibitor who have not
received previous exemestane
Published
Feb-17
(<£1m p/a for
England)
Dec-16
£8.9m (based on list price).
Related documents